Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The bone is a common site for metastasis in patients with advanced prostate carcinoma, and provides a 'fertile' milieu which stimulates tumour growth and associated bone disease. For years, the concept of treatment strategies has remained targeting the tumour itself; however, the occurrence of chemoresistance remains a challenge now more than ever. The attraction of targeting the bone microenvironment in order to disrupt tumour localisation and proliferation stems from the idea that stromal cells are superiorly stable at a genetic level, thus decreasing the risk of resistance manifestation. In this review, we will discuss recent findings with regards to the pathogenesis of prostate cancer-induced bone disease and recent therapeutic strategies in an aim to evaluate the ever increasing role of the microenvironment in disease progression.

Original publication




Journal article


Curr osteoporos rep

Publication Date





170 - 177


Bone metastasis, Bone microenvironment, Prostate cancer, Therapeutic strategies, Adipocytes, Angiogenesis Inhibitors, Antineoplastic Agents, Bevacizumab, Bone Density Conservation Agents, Bone Marrow Cells, Bone Neoplasms, Bone and Bones, Carcinoma, Denosumab, Diphosphonates, Humans, Male, Mesenchymal Stem Cells, Molecular Targeted Therapy, Osteoblasts, Osteoclasts, Prostatic Neoplasms, Radioisotopes, Radium, Tumor Microenvironment